Results 191 to 200 of about 50,213 (312)

Fidelity of Sensory Reinnervation in Peroneal and Sural Nerves to Lumbar Dorsal Root Ganglia 4 and 5 After Segmental Injury to the Sciatic Nerve

open access: yesEuropean Journal of Neuroscience, Volume 63, Issue 5, March 2026.
Fidelity of sensory axon reinnervation was greater into the peroneal nerve, which is a mixed sensorimotor nerve, compared to the sural nerve, which is a sensory nerve. This finding suggests sensory regeneration of segmental branched defects may be improved using anatomically matching branched grafts.
JuliAnne Allgood   +2 more
wiley   +1 more source

Calcitonin gene-related peptide [PDF]

open access: yes, 1993
Bosch, Ruud J. L. H.   +5 more
core   +1 more source

Surgical Interventions in Idiopathic Intracranial Hypertension—A Comprehensive Multi‐Center Study of Outcome and the Role of Treatment Indication

open access: yesEuropean Journal of Neurology, Volume 33, Issue 3, March 2026.
In this multicenter retrospective study of idiopathic intracranial hypertension, only 3.6% of patients required surgery, predominantly for acute visual deterioration. Both cerebrospinal fluid diversion and optic nerve sheath fenestration were effective in improving visual outcomes and resolving papilledema, while headache improvement was limited ...
Gabriel Bsteh   +24 more
wiley   +1 more source

Transplantation and Erectile Dysfunction [PDF]

open access: yes, 1992
Djamilian, Mohamad H.   +4 more
core   +1 more source

Additional file 1 of Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis

open access: green
Marina Romozzi   +10 more
openalex   +1 more source

Long‐Term Improvements Following Initial Migraine Response in Eptinezumab‐Treated Participants With Migraine for Whom 2–4 Prior Preventive Treatments Have Failed

open access: yesEuropean Journal of Neurology, Volume 33, Issue 3, March 2026.
This post hoc analysis of data from the DELIVER trial evaluated long‐term maintenance of early ≥ 50% and ≥ 75% migraine response. For both eptinezumab doses (100 or 300 mg), ≥ 50% or ≥ 75% migraine response over Weeks 1–12 or 1–24 was maintained for the entire 72‐week treatment period for many participants.
Jessica Ailani   +7 more
wiley   +1 more source

Migraine-induced cochlear injury triggers ZBP1-mediated PANoptosis via CGRP signaling. [PDF]

open access: yesJ Headache Pain
Xu W   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy